First City Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

First City Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-223	Closed	-$234K	–	165
2024 Q3	$234K	Hold	223	–	–	0.12%	149
2024 Q2	$234K	Hold	223	–	–	0.13%	146
2024 Q1	$215K	Buy	+223	New	+$212K	0.12%	164
2022 Q2	–	Sell	-293	Closed	-$205K	–	171
2022 Q1	$205K	Buy	+293	New	+$185K	0.11%	164
2020 Q4	–	Sell	-411	Closed	-$247K	–	193
2020 Q3	$247K	Buy	+411	New	+$249K	0.09%	169
2016 Q2	–	Sell	-241	Closed	-$86.9K	–	435
2016 Q1	$86.9K	Sell	241 -40	-14%	-$16.5K	0.06%	209
2015 Q4	$153K	Sell	281 -30	-10%	-$16.3K	0.1%	157
2015 Q3	$145K	Hold	311	–	–	0.11%	161
2015 Q2	$159K	Buy	311 +171	+122%	+$83.5K	0.11%	163
2015 Q1	$63.2K	Buy	140 +40	+40%	+$17K	0.04%	252
2014 Q4	$41K	Hold	100	–	–	0.03%	294
2014 Q3	$36.1K	Hold	100	–	–	0.03%	300
2014 Q2	$28.2K	Hold	100	–	–	0.02%	340
2014 Q1	$30K	Buy	+100	New	+$30.8K	0.02%	328

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First City Capital Management's REGN Position: Q4 2024 in Review

First City Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 223 shares — an estimated $234K sold.

First City Capital Management first reported a position in REGN in Q1 2014 and held it in 14 quarters. The position peaked at $247K in Q3 2020. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

First City Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
First City Capital Management sold 223 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $234K.
First City Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 14 quarters.
First City Capital Management's Regeneron Pharmaceuticals position peaked at $247K in Q3 2020.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on First City Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.